The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset

Craig J. Ceol, Yariv Houvras, Judit Jane-Valbuena, Steve Bilodeau, David A. Orlando, Valentine Battisti, Lauriane Fritsch, William M. Lin, Travis J. Hollmann, Fabrizio Ferré, Caitlin Bourque, Christopher J. Burke, Laura Turner, Audrey M. Uong, Laura A. Johnson, Rameen Beroukhim, Craig H. Mermel, Massimo Loda, Slimane Ait-Si-Ali, Levi A. Garraway & 2 others Richard A. Young, Leonard I. Zon

Research output: Contribution to journalArticle

266 Citations (Scopus)

Abstract

The most common mutation in human melanoma, BRAF(V600E), activates the serine/threonine kinase BRAF and causes excessive activity in the mitogen-activated protein kinase pathway. BRAF(V600E) mutations are also present in benign melanocytic naevi, highlighting the importance of additional genetic alterations in the genesis of malignant tumours. Such changes include recurrent copy number variations that result in the amplification of oncogenes. For certain amplifications, the large number of genes in the interval has precluded an understanding of the cooperating oncogenic events. Here we have used a zebrafish melanoma model to test genes in a recurrently amplified region of chromosome 1 for the ability to cooperate with BRAF(V600E) and accelerate melanoma. SETDB1, an enzyme that methylates histone H3 on lysine 9 (H3K9), was found to accelerate melanoma formation significantly in zebrafish. Chromatin immunoprecipitation coupled with massively parallel DNA sequencing and gene expression analyses uncovered genes, including HOX genes, that are transcriptionally dysregulated in response to increased levels of SETDB1. Our studies establish SETDB1 as an oncogene in melanoma and underscore the role of chromatin factors in regulating tumorigenesis.

Original languageEnglish (US)
Pages (from-to)513-518
Number of pages6
JournalNature
Volume471
Issue number7339
DOIs
StatePublished - Mar 24 2011
Externally publishedYes

Fingerprint

Melanoma
Zebrafish
Oncogenes
Genes
Pigmented Nevus
High-Throughput Nucleotide Sequencing
Mutation
Chromatin Immunoprecipitation
Chromosomes, Human, Pair 1
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinases
DNA Sequence Analysis
Histones
Lysine
Chromatin
Carcinogenesis
histone methyltransferase
Gene Expression
Enzymes
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • General

Cite this

Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., ... Zon, L. I. (2011). The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature, 471(7339), 513-518. https://doi.org/10.1038/nature09806

The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. / Ceol, Craig J.; Houvras, Yariv; Jane-Valbuena, Judit; Bilodeau, Steve; Orlando, David A.; Battisti, Valentine; Fritsch, Lauriane; Lin, William M.; Hollmann, Travis J.; Ferré, Fabrizio; Bourque, Caitlin; Burke, Christopher J.; Turner, Laura; Uong, Audrey M.; Johnson, Laura A.; Beroukhim, Rameen; Mermel, Craig H.; Loda, Massimo; Ait-Si-Ali, Slimane; Garraway, Levi A.; Young, Richard A.; Zon, Leonard I.

In: Nature, Vol. 471, No. 7339, 24.03.2011, p. 513-518.

Research output: Contribution to journalArticle

Ceol, CJ, Houvras, Y, Jane-Valbuena, J, Bilodeau, S, Orlando, DA, Battisti, V, Fritsch, L, Lin, WM, Hollmann, TJ, Ferré, F, Bourque, C, Burke, CJ, Turner, L, Uong, AM, Johnson, LA, Beroukhim, R, Mermel, CH, Loda, M, Ait-Si-Ali, S, Garraway, LA, Young, RA & Zon, LI 2011, 'The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset', Nature, vol. 471, no. 7339, pp. 513-518. https://doi.org/10.1038/nature09806
Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011 Mar 24;471(7339):513-518. https://doi.org/10.1038/nature09806
Ceol, Craig J. ; Houvras, Yariv ; Jane-Valbuena, Judit ; Bilodeau, Steve ; Orlando, David A. ; Battisti, Valentine ; Fritsch, Lauriane ; Lin, William M. ; Hollmann, Travis J. ; Ferré, Fabrizio ; Bourque, Caitlin ; Burke, Christopher J. ; Turner, Laura ; Uong, Audrey M. ; Johnson, Laura A. ; Beroukhim, Rameen ; Mermel, Craig H. ; Loda, Massimo ; Ait-Si-Ali, Slimane ; Garraway, Levi A. ; Young, Richard A. ; Zon, Leonard I. / The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. In: Nature. 2011 ; Vol. 471, No. 7339. pp. 513-518.
@article{4bc8f71ae4ce4bdea532241dedde7b87,
title = "The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset",
abstract = "The most common mutation in human melanoma, BRAF(V600E), activates the serine/threonine kinase BRAF and causes excessive activity in the mitogen-activated protein kinase pathway. BRAF(V600E) mutations are also present in benign melanocytic naevi, highlighting the importance of additional genetic alterations in the genesis of malignant tumours. Such changes include recurrent copy number variations that result in the amplification of oncogenes. For certain amplifications, the large number of genes in the interval has precluded an understanding of the cooperating oncogenic events. Here we have used a zebrafish melanoma model to test genes in a recurrently amplified region of chromosome 1 for the ability to cooperate with BRAF(V600E) and accelerate melanoma. SETDB1, an enzyme that methylates histone H3 on lysine 9 (H3K9), was found to accelerate melanoma formation significantly in zebrafish. Chromatin immunoprecipitation coupled with massively parallel DNA sequencing and gene expression analyses uncovered genes, including HOX genes, that are transcriptionally dysregulated in response to increased levels of SETDB1. Our studies establish SETDB1 as an oncogene in melanoma and underscore the role of chromatin factors in regulating tumorigenesis.",
author = "Ceol, {Craig J.} and Yariv Houvras and Judit Jane-Valbuena and Steve Bilodeau and Orlando, {David A.} and Valentine Battisti and Lauriane Fritsch and Lin, {William M.} and Hollmann, {Travis J.} and Fabrizio Ferr{\'e} and Caitlin Bourque and Burke, {Christopher J.} and Laura Turner and Uong, {Audrey M.} and Johnson, {Laura A.} and Rameen Beroukhim and Mermel, {Craig H.} and Massimo Loda and Slimane Ait-Si-Ali and Garraway, {Levi A.} and Young, {Richard A.} and Zon, {Leonard I.}",
year = "2011",
month = "3",
day = "24",
doi = "10.1038/nature09806",
language = "English (US)",
volume = "471",
pages = "513--518",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7339",

}

TY - JOUR

T1 - The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset

AU - Ceol, Craig J.

AU - Houvras, Yariv

AU - Jane-Valbuena, Judit

AU - Bilodeau, Steve

AU - Orlando, David A.

AU - Battisti, Valentine

AU - Fritsch, Lauriane

AU - Lin, William M.

AU - Hollmann, Travis J.

AU - Ferré, Fabrizio

AU - Bourque, Caitlin

AU - Burke, Christopher J.

AU - Turner, Laura

AU - Uong, Audrey M.

AU - Johnson, Laura A.

AU - Beroukhim, Rameen

AU - Mermel, Craig H.

AU - Loda, Massimo

AU - Ait-Si-Ali, Slimane

AU - Garraway, Levi A.

AU - Young, Richard A.

AU - Zon, Leonard I.

PY - 2011/3/24

Y1 - 2011/3/24

N2 - The most common mutation in human melanoma, BRAF(V600E), activates the serine/threonine kinase BRAF and causes excessive activity in the mitogen-activated protein kinase pathway. BRAF(V600E) mutations are also present in benign melanocytic naevi, highlighting the importance of additional genetic alterations in the genesis of malignant tumours. Such changes include recurrent copy number variations that result in the amplification of oncogenes. For certain amplifications, the large number of genes in the interval has precluded an understanding of the cooperating oncogenic events. Here we have used a zebrafish melanoma model to test genes in a recurrently amplified region of chromosome 1 for the ability to cooperate with BRAF(V600E) and accelerate melanoma. SETDB1, an enzyme that methylates histone H3 on lysine 9 (H3K9), was found to accelerate melanoma formation significantly in zebrafish. Chromatin immunoprecipitation coupled with massively parallel DNA sequencing and gene expression analyses uncovered genes, including HOX genes, that are transcriptionally dysregulated in response to increased levels of SETDB1. Our studies establish SETDB1 as an oncogene in melanoma and underscore the role of chromatin factors in regulating tumorigenesis.

AB - The most common mutation in human melanoma, BRAF(V600E), activates the serine/threonine kinase BRAF and causes excessive activity in the mitogen-activated protein kinase pathway. BRAF(V600E) mutations are also present in benign melanocytic naevi, highlighting the importance of additional genetic alterations in the genesis of malignant tumours. Such changes include recurrent copy number variations that result in the amplification of oncogenes. For certain amplifications, the large number of genes in the interval has precluded an understanding of the cooperating oncogenic events. Here we have used a zebrafish melanoma model to test genes in a recurrently amplified region of chromosome 1 for the ability to cooperate with BRAF(V600E) and accelerate melanoma. SETDB1, an enzyme that methylates histone H3 on lysine 9 (H3K9), was found to accelerate melanoma formation significantly in zebrafish. Chromatin immunoprecipitation coupled with massively parallel DNA sequencing and gene expression analyses uncovered genes, including HOX genes, that are transcriptionally dysregulated in response to increased levels of SETDB1. Our studies establish SETDB1 as an oncogene in melanoma and underscore the role of chromatin factors in regulating tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=79953056443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953056443&partnerID=8YFLogxK

U2 - 10.1038/nature09806

DO - 10.1038/nature09806

M3 - Article

VL - 471

SP - 513

EP - 518

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7339

ER -